首页|达格列净联合二甲双胍在2型糖尿病并发冠心病临床治疗中的应用优势

达格列净联合二甲双胍在2型糖尿病并发冠心病临床治疗中的应用优势

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
目的 探究达格列净联合二甲双胍在 2 型糖尿病并发冠心病中的治疗效果。方法 选取 2021 年 6 月～2023 年 6 月收治的 2 型糖尿病并发冠心病患者 80 例。采用随机数字表法分为观察组(40 例)、对照组(40 例)。对照组给予二甲双胍治疗，观察组在对照组基础上给予达格列净联合治疗。比较两组临床疗效及氨基末端B型利钠肽前体(N-terminal b-type natriuretic peptide precursor，NT-proBNP)、空腹血糖(Fasting blood glucose，FPG)、糖化血红蛋白(Glycosylated hemoglobin，HbA1c)、C反应蛋白(C-reactive protein，CRP)、同型半胱氨酸(Homocysteine，Hcy)、尿酸(Uric acid，UA)水平;统计不良反应发生率。结果 观察组的治疗总有效率(37 例/40 例，92。50%)高于对照组(32 例/40 例，80。00%)(P＜0。05)。治疗后两组的NT-proBNP、FPG、HbA1c水平均下降(P＜0。05)。治疗后两组的CRP、Hcy、UA水平均下降(P＜0。05)。两组的不良反应总发生率对比，差异无统计学意义(P＞0。05)。结论 达格列净联合二甲双胍在 2 型糖尿病并发冠心病的治疗中有较好的疗效，能够改善患者的心功能，调节其血糖水平，并抑制患者机体的炎症反应。
Application advantages of dapagliflozin combined with metformin in the clinical treatment of type 2 diabetes complicated with coronary heart disease
Objective To explore the therapeutic effect of dapagliflozin combined with metformin in type 2 diabetes patients with coronary heart disease.Methods A total of 80 patients with type 2 diabetes complicated with coronary heart disease were selected from June 2021 to June 2023,and divided into the observation group(40 cases)and the control group(40 cases)by random number table method.The control group was given metformin treatment,and the observation group was given dapagliflozin combined treatment based on the control group.The clinical efficacy and the levels of NT-proBNP,FPG,HbA1c,CRP,Hcy,UA were compared between the two groups,and the incidence of adverse reactions was measured.Results The total effective rate of the observation group(37 cases/40 cases,92.50%)was higher than that of the control group(32 cases/40 cases,80.00%)(P＜0.05).After treatment,the levels of NT-proBNP,FPG and HbA1c were decreased in both groups(P＜0.05).After treatment,the levels of CRP,Hcy and UA decreased in both groups(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Dapagliflozin combined with metformin has a good effect in the treatment of type 2 diabetes com-plicated with coronary heart disease,which can improve the heart function of patients,regulate their blood sugar level,and inhibit the inflammatory reaction of patients..

Type 2 diabetesCoronary heart diseaseDapagliflozin:Metformin

马海文

展开 >

芜湖市眼科医院(弋江区医院)内科,安徽芜湖 241000

2型糖尿病 冠心病 达格列净 二甲双胍

2024

中国处方药
南方医药经济研究所

中国处方药

影响因子：0.649
ISSN：1671-945X
年,卷(期)：2024.22(5)
  • 20